Role of neutralizing (maternal) antibodies in protection against human parechovirus infection and other risk factors for picornavirus infection in young children.

Role of neutralizing (maternal) antibodies in protection against human parechovirus infection and other risk factors for picornavirus infection in young children. - Role of antibodies in human parechovirus infection in young children.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33777

Enrollment

216

Registered

2009-05-18

Start date

2009-05-28

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infection with human parechovirus meningitis/sepsis like illness

Interventions

None listed

Eligibility

Age

2 Years to 99 Years

Inclusion criteria

Inclusion criteria: Infants under the age of 1 year, positive for HPeV in CSF, stool, nasopharynx and/or blood obtained for diagnostic purposes and detected by routine PCR. Controls under the age of 1 year will be randomly selected from the diagnostic CSF, stool, nasopharynx and/or blood samples positive for EV PCR and negative for EV/HPeV PCR, and matched for age. The mothers of those infants. Written informed consent.

Exclusion criteria

Exclusion criteria: No informed consent

Design outcomes

Primary

Measure	Time frame
- HPeV specific antibodytiters - Severity of disease	—

Secondary

Measure	Time frame
- Cytokine production - Genetic variables: CTLA-4 polymorphism and expression of Toll Like Receptors - Duration of shedding of HPeV - Viral load of HPeV	—

Countries

Netherlands

Outcome results